Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow ACADIA PHARMACEUTICALS INC

Get SEC filing alerts via email and in your feed for ACADIA PHARMACEUTICALS INC

ACAD

ACADIA PHARMACEUTICALS INC

About ACADIA PHARMACEUTICALS INC

Acadia Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing innovative treatments for central nervous system disorders and rare diseases. Its key products include NUPLAZID for Parkinson's disease psychosis and DAYBUE for Rett syndrome, both of which address significant unmet medical needs. With a focus on expanding its pipeline and global reach, Acadia is advancing multiple clinical trials, including therapies for Prader-Willi syndrome and Alzheimer's disease psychosis.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from ACADIA PHARMACEUTICALS INC

1
1
ACADIA PHARMACEUTICALS INC ACADIA Pharmaceuticals Reports Q1 2026 Revenue Growth to $268.1 Million, Net Income Declines

Via official filing (AI summary) | 30 days ago | 0 comments

2
1
ACADIA PHARMACEUTICALS INC ACADIA Pharmaceuticals Reports $1.07 Billion in Net Product Sales for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
ACADIA PHARMACEUTICALS INC ACADIA Pharmaceuticals Reports 11.3% Revenue Growth to $278.6 Million in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
ACADIA PHARMACEUTICALS INC ACADIA Pharmaceuticals Reports Q2 2025 Financial Results with Revenue Growth and Decreased Net Income

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
ACADIA PHARMACEUTICALS INC ACADIA Pharmaceuticals Reports Q1 2025 Financial Results with Increased Revenue and Net Income

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
ACADIA PHARMACEUTICALS INC ACADIA Pharmaceuticals Reports 32% Revenue Growth to $957.8 Million in 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
ACADIA PHARMACEUTICALS INC Acadia Pharmaceuticals Reports Strong Q3 2024 Financials, Net Income Turnaround

Via official filing (AI summary) | over 1 year ago | 0 comments